PPDI to Go Private - Analyst Blog
October 07 2011 - 5:15AM
Zacks
Pharmaceutical drug research company Pharmaceutical
Product Development, Inc. (PPDI) recently announced that
it has entered into an agreement to be acquired by privately held
The Carlyle Group and Hellman & Friedman for $3.9 billion in
cash.
PPD shareholders have been offered a cash consideration of
$33.25 per share, a premium of 29.6% over the stock’s closing price
on September 30. The transaction has won unanimous approval of
PPD’s board while shareholder approval is awaited. The transaction
is expected to close in the fourth quarter of 2011, following which
PPD will become a private company and will no longer trade on
NASDAQ.
Four banks have committed to finance the deal. These include
Credit Suisse, JP Morgan (JPM),
Goldman Sachs (GS) and UBS (UBS).
PPD has 30 days to solicit superior proposals from other contending
bidders. Because of the buyout, PPD will not hold a conference call
to discuss the third quarter results.
Our Recommendation
We currently have a Hold recommendation on PPD. The company
retains a Zacks #3 Rank, which translates into a short-term Hold
rating. We are impressed by the company’s strong bookings, stable
backlog duration and sound expense control.
PPD is a leading contract research organization (CRO) providing
drug discovery and development services to pharmaceutical and
biotechnology companies. Companies like PPD and Charles
River Laboratories (CRL) suffered in 2008-2009 due to a
decline in demand for their services in time of a depressed
economy.
The environment for CROs is gradually improving. The improving
request for proposals (RFP) flows and key strategic partnerships
secured by PPD with bio-pharma customers are a testament to such a
revival, which would in turn result in bottom-line growth. However,
we remain concerned about the high cancellation rates.
GOLDMAN SACHS (GS): Free Stock Analysis Report
JPMORGAN CHASE (JPM): Free Stock Analysis Report
PHARMA PROD DEV (PPDI): Free Stock Analysis Report
UBS AG (UBS): Free Stock Analysis Report
Zacks Investment Research
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pharmaceutical Product Developme (NASDAQ:PPDI)
Historical Stock Chart
From Apr 2023 to Apr 2024